PMID- 22986578
OWN - NLM
STAT- MEDLINE
DCOM- 20130809
LR  - 20130213
IS  - 1476-5608 (Electronic)
IS  - 1365-7852 (Linking)
VI  - 16
IP  - 1
DP  - 2013 Mar
TI  - A meta-analysis of efficacy and safety of the new alpha1A-adrenoceptor-selective 
      antagonist silodosin for treating lower urinary tract symptoms associated with 
      BPH.
PG  - 79-84
LID - 10.1038/pcan.2012.36 [doi]
AB  - BACKGROUND: Recently several clinical trials have focused on the efficacy and 
      safety of silodosin, a new, highly selective alpha1A-blocker. We tried to verify 
      silodosin's superiority to placebo and non-inferiority to tamsulosin in treating 
      patients with lower urinary tract symptoms (LUTS) associated with BPH. METHODS: 
      All randomized placebo- and active- controlled trials with silodosin were 
      included systematically using Medline, Embase and The Cochrane Library. Primary 
      outcome was International Prostate Symptom Score (IPSS) and IPSS subsores; 
      secondary outcomes were peak urinary flow rate (Q(max)), quality of life (QoL) 
      and primary adverse events (AEs) included retrograde ejaculation, dizziness and 
      headache. RESULTS: The data of the included randomized controlled trials (RCTs) 
      were collected, extracted, and assessed by our protocol. Five RCTs including a 
      total of 2595 patients were identified. Meta-analysis indicated that silodosin 
      achieved significant improvement versus placebo in total IPSS, in IPSS subscores, 
      and in Q(max); silodosin showed a greater improvement in voiding symptoms than 
      tamsulosin, and a higher incidence of retrograde ejaculation than placebo and 
      tamsulosin. No significant differences were observed in total IPSS, in IPSS 
      storage symptoms, in Q(max) and in QoL when compared with tamsulosin. Silodosin 
      was associated with the same low incidence of dizziness and headache with placebo 
      and tamsulosin. CONCLUSIONS: Silodosin is an effective and well-tolerated 
      treatment for both voiding and storage symptoms in patients with LUTS associated 
      with BPH. Despite with increased retrograde ejaculation, its overall efficacy is 
      not inferior to tamsulosin, while at the same time being possibly superior to 
      tamsulosin.
FAU - Wu, Y J
AU  - Wu YJ
AD  - Department of Urology, West China Hospital of Sichuan University, Chengdu, China.
FAU - Dong, Q
AU  - Dong Q
FAU - Liu, L R
AU  - Liu LR
FAU - Wei, Q
AU  - Wei Q
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20120918
PL  - England
TA  - Prostate Cancer Prostatic Dis
JT  - Prostate cancer and prostatic diseases
JID - 9815755
RN  - 0 (Adrenergic alpha-1 Receptor Antagonists)
RN  - 0 (Indoles)
RN  - CUZ39LUY82 (silodosin)
SB  - IM
MH  - Adrenergic alpha-1 Receptor Antagonists/*therapeutic use
MH  - Humans
MH  - Indoles/*therapeutic use
MH  - Lower Urinary Tract Symptoms/*drug therapy/*etiology
MH  - Male
MH  - Prostatic Hyperplasia/*complications
EDAT- 2012/09/19 06:00
MHDA- 2013/08/10 06:00
CRDT- 2012/09/19 06:00
PHST- 2012/09/19 06:00 [entrez]
PHST- 2012/09/19 06:00 [pubmed]
PHST- 2013/08/10 06:00 [medline]
AID - pcan201236 [pii]
AID - 10.1038/pcan.2012.36 [doi]
PST - ppublish
SO  - Prostate Cancer Prostatic Dis. 2013 Mar;16(1):79-84. doi: 10.1038/pcan.2012.36. 
      Epub 2012 Sep 18.